Table 1.
Study, dosing regimen, number of injections and change in ETDRS letters
| Study | Regimen | Drug | Baseline BCVA (ETDRS Letter) | # Injections (1 year) | Change in ETDRS Letter (1 year) |
| ANCHOR | q4 | Ranibizumab | 53.7 | 11.2 | 11.3 |
| MARINA | q4 | Ranibizumab | 47.1 | 12.3 | 7.2 |
| VIEW 1 | q4 | Aflibercept | 55.2 | 12.3 | 10.9 |
| VIEW 1 | q8 | Aflibercept | 55.7 | 7.5 | 7.9 |
| VIEW 1 | q4 | Ranibizumab | 54 | 12.3 | 8.1 |
| VIEW 2 | q4 | Aflibercept | 52.8 | 12.3 | 7.6 |
| VIEW 2 | q8 | Aflibercept | 51.6 | 7.5 | 8.9 |
| VIEW 2 | q4 | Ranibizumab | 53.8 | 12.3 | 9.4 |
| PRONTO | PRN | Ranibizumab | 56.2 | 5.3 | 9.6 |
| SUSTAIN | PRN | Ranibizumab | 56.1 | 5.6 | 3.6 |
| HARBOR | q4 | Ranibizumab | 54.2 | 11.3 | 10.1 |
| HARBOR | PRN | Ranibizumab | 54.5 | 7.7 | 8.2 |
| CATT | q4 | Bevacizumab | 60.2 | 11.9 | 8 |
| CATT | PRN | Bevacizumab | 60.4 | 7.7 | 5.9 |
| CATT | PRN | Ranibizumab | 61.5 | 6.9 | 6.8 |
| CATT | q4 | Ranibizumab | 60.1 | 11.7 | 8.5 |
| IVAN | q4 | Bevacizumab | 60 | 12 | 6.8 |
| IVAN | PRN | Mixed | 62.9 | 7 | 5.5 |
| PIER | q12 | Ranibizumab | 53.7 | 6 | −0.2 |
| EXCITE | q12 | Ranibizumab | 57.5 | 5.5 | 3.8 |
| HAWK | q12/q8 | Brolucizumab (3 mg)† | 60.6 | 6.7* | 6.1 |
| HAWK | q12/q8 | Brolucizumab (6 mg) | 60.6 | 6.6* | 6.6 |
| HAWK | q8 | Aflibercept | 60.6 | 8 | 6.8 |
| HARRIER | q12/q8 | Brolucizumab (6 mg) | 61.2 | 6.7* | 6.9 |
| HARRIER | q8 | Aflibercept | 61.2 | 8 | 7.6 |
| LUCAS | T&E | Ranibizumab | 61.6 | 8 | 8.2 |
| LUCAS | T&E | Bevacizumab | 59.6 | 8.9 | 7.9 |
| TREX-AMD | q4 | Ranibizumab | 60.3 | 13 | 9.2 |
| TREX-AMD | T&E | Ranibizumab | 59.9 | 10.1 | 10.5 |
| TREND | T&E | Ranibizumab | 59.5 | 8.7 | 6.2 |
| TREND | q4 | Ranibizumab | 60.6 | 11.1 | 8.1 |
| CEDAR | q8 | Abicipar | 56 | 8 | 6.7 |
| CEDAR | q12 | Abicipar | 56 | 6 | 5.6 |
| CEDAR | q4 | Ranibizumab | 56 | 13 | 8.5 |
| SEQUOIA | q8 | Abicipar | 57.2 | 8 | 8.3 |
| SEQUOIA | q12 | Abicipar | 56.4 | 6 | 7.3 |
| SEQUOIA | q4 | Ranibizumab | 57.1 | 13 | 8.3 |
*Extrapolated based on the study design given variable dosing in single study arm with weighted average based on minimum number of injections received (6) and maximum average injections received (7.5). Bolded studies are level 1 FDA registration and National Eye Institute trials which are included in the analysis.
†Brolucizumab 3 mg dose is the triangle data point in figure 1.
ANCHOR, Anti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularization in AMD; BCVA, best corrected visual acuity; CATT, Comparison of Age-Related Macular Degeneration Treatments Trials; ETDRS, early treatment of diabetic retinopathy; EXCITE, Efficacy and Safety of Ranibizumab in subjects with Subfoveal and CNV secondary to AMD; FDA, Food and Drug Administration; LUCAS, Lucentis Compared to Avastin Study ; MARINA, Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular AMD; PRN, pro re nata; PrONTO, Prospective Optical Coherence Tomography (OCT) Imaging of Patients with Neovascular AMD Treated with intra-Ocular Ranibizumab; q4, every 4 weeks; q8, every 8 weeks; q12, every 12 weeks; SUSTAIN, Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration; T&E, treat and extend; TREX-AMD, Treat and Extend Protocol in Patients with Wet Age-Related Macular Degeneration; VIEW, The VEGF Trap Eye: Investigation of Efficacy and Safety in Wet AMD study.